Effect of Chlorhexidine Cleansing on Skin Flora of Newborns in Nepal

NCT ID: NCT00271440

Last Updated: 2010-04-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

286 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2006-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the reductions in skin flora of newborns after a single cleansing of the body with three concentrations of chlorhexidine (0.25%, 0.5%, 1.0%) and to examine the safety of skin cleansing in neonates in Nepal.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Studies in Malawi, Egypt, and Nepal suggest that neonatal skin cleansing with chlorhexidine solutions may reduce the risk of infection and mortality. Cleansing with 0.25% chlorhexidine in Nepal resulted in a 28% reduction in mortality among low birth weight infants, while there was no impact on infants of normal weight. The mechanism of action for this observed benefit is not clear. Chlorhexidine may remove pathogens from the skin of the newborn and/or prevent exposure to pathogens that may otherwise cause infection and lead to sepsis. The benefit of chlorhexidine cleansing may be extended with higher concentrations of chlorhexidine.

Infants born at the Tribhuvan University Teaching Hospital in Katmandu, Nepal will be randomized to skin cleansing with chlorhexidine at one of three concentrations (0.25%, 0.50%, 1.00%). Skin swabs will be collected before wiping, and two and twenty-four hours after wiping in order to compare levels of bacteria on the skin across the treatment groups. A small quantity of blood will be collected at 24 hours after wiping to determine the potential for absorption of chlorhexidine

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacterial Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CHX 1.0%

1.0% CHX wiping

Group Type EXPERIMENTAL

skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)

Intervention Type PROCEDURE

CHX 0.5%

0.5% Chlorhexidine

Group Type EXPERIMENTAL

skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)

Intervention Type PROCEDURE

CHX 0.25%

chlorhexidine cleansing with pre-soaked pre-sealed wipe

Group Type EXPERIMENTAL

skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* babies born at Tribhuvan University Teaching Hospital
* greater than 1500 grams

Exclusion Criteria

* less than 1500 grams
* requires major surgical procedure
* clinically evident skin infection
* generalized skin disease
* major congenital anomoly
Maximum Eligible Age

3 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tribhuvan University, Nepal

OTHER

Sponsor Role collaborator

Nepal Nutrition Intervention Project Sarlahi

OTHER

Sponsor Role collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Luke C Mullany, PhD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins Bloomberg School of Public Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tribhuvan University Teaching Hospital

Kathmandu, , Nepal

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Nepal

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01HD044004

Identifier Type: NIH

Identifier Source: secondary_id

View Link

R01-HD44004-2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.